Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
AT Shaw, GJ Riely, Y-J Bang, D-W Kim, DR Camidge, BJ Solomon, M Varella-Garcia, AJ Iafrate, G Shapiro, T Usari, SC Wang, KD Wilner, JW Clark, S-H Ou
Annals of Oncology | OXFORD UNIV PRESS | Published : 2019
BACKGROUND: In the ongoing phase 1 PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001. PATIENTS AND METHODS: ROS1 status was determined by fluorescence in situ hybridization or reverse transcriptase-polymerase chain reaction. All patients received crizotinib at a starting dose of 250 mg twice daily. RESULTS: Fifty-three patients received crizotinib, with a median duration of treatment of 22.4 months. At data cut-off, treatment ..View full abstract
The PROFILE 1001 study (NCT00585195) and preparation of the manuscript were supported by Pfizer Inc. Editorial support was provided by Cherry Bwalya, Jade Drummond and Simon Lancaster of in Science Communications, Springer Healthcare (Chester, UK), and was funded by Pfizer Inc.